Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey.

Lavorgna L, Esposito S, Lanzillo R, Sparaco M, Ippolito D, Cocco E, Fenu G, Borriello G, De Mercanti S, Frau J, Capuano R, Trojsi F, Rosa L, Clerico M, Laroni A, Morra VB, Tedeschi G, Bonavita S.

J Neurol. 2019 Jan 16. doi: 10.1007/s00415-019-09193-4. [Epub ahead of print]

PMID:
30649617
2.

Enhancing natural killer cells is beneficial in multiple sclerosis - Yes.

Laroni A.

Mult Scler. 2018 Nov 13:1352458518800776. doi: 10.1177/1352458518800776. [Epub ahead of print] No abstract available.

PMID:
30421641
3.

No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.

Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group.

J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26.

PMID:
30259178
4.

Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report.

Lapucci C, Gualandi F, Mikulska M, Palmeri S, Mancardi G, Uccelli A, Laroni A.

Mult Scler Relat Disord. 2018 Nov;26:52-54. doi: 10.1016/j.msard.2018.09.006. Epub 2018 Sep 11.

PMID:
30223229
5.

Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study.

Saccà F, Lanzillo R, Signori A, Maniscalco GT, Signoriello E, Lo Fermo S, Repice A, Annovazzi P, Baroncini D, Clerico M, Binello E, Cerqua R, Mataluni G, Bonavita S, Lavorgna L, Zarbo IR, Laroni A, Rossi S, Pareja Gutierrez L, La Gioia S, Frigeni B, Barcella V, Frau J, Cocco E, Fenu G, Torri Clerici V, Sartori A, Rasia S, Cordioli C, Di Sapio A, Pontecorvo S, Grasso R, Barrilà C, Russo CV, Esposito S, Ippolito D, Bovis F, Gallo F, Sormani MP; ; On behalf of the iMUST Group.

Mult Scler. 2018 Jul 25:1352458518790390. doi: 10.1177/1352458518790390. [Epub ahead of print]

PMID:
30044207
6.

Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation.

Giordana MT, Cavalla P, Uccelli A, Laroni A, Bandini F, Vercellino M, Mancardi G.

Mult Scler. 2018 Jul;24(8):1133-1137. doi: 10.1177/1352458518763095. Epub 2018 Apr 30.

PMID:
29708466
7.

A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.

Lanzillo R, Prosperini L, Gasperini C, Moccia M, Fantozzi R, Tortorella C, Nociti V, Annovazzi P, Cavalla P, Radaelli M, Malucchi S, Clerici VT, Boffa L, Buttari F, Ragonese P, Maniscalco GT, Di Filippo M, Buscarinu MC, Pinardi F, Gallo A, Coghe G, Pesci I, Laroni A, Gajofatto A, Calabrese M, Tomassini V, Cocco E, Solaro C; R.I.Re.MS study group.

J Neurol. 2018 May;265(5):1174-1183. doi: 10.1007/s00415-018-8831-x. Epub 2018 Mar 16.

PMID:
29549468
8.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e823-e831. doi: 10.1212/WNL.0000000000005067. Epub 2018 Feb 7.

PMID:
29438046
9.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.

Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Solaro C, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e832-e839. doi: 10.1212/WNL.0000000000005068. Epub 2018 Feb 7.

PMID:
29438041
10.

Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study.

Laroni A, Signori A, Maniscalco GT, Lanzillo R, Russo CV, Binello E, Lo Fermo S, Repice A, Annovazzi P, Bonavita S, Clerico M, Baroncini D, Prosperini L, La Gioia S, Rossi S, Cocco E, Frau J, Torri Clerici V, Signoriello E, Sartori A, Zarbo IR, Rasia S, Cordioli C, Cerqua R, Di Sapio A, Lavorgna L, Pontecorvo S, Barrilà C, Saccà F, Frigeni B, Esposito S, Ippolito D, Gallo F, Sormani MP; iMUST group.

Neurology. 2017 Nov 28;89(22):2222-2229. doi: 10.1212/WNL.0000000000004686. Epub 2017 Nov 1.

PMID:
29093064
11.

Teriflunomide treatment reduces B cells in patients with MS.

Gandoglia I, Ivaldi F, Laroni A, Benvenuto F, Solaro C, Mancardi G, Kerlero de Rosbo N, Uccelli A.

Neurol Neuroimmunol Neuroinflamm. 2017 Oct 23;4(6):e403. doi: 10.1212/NXI.0000000000000403. eCollection 2017 Nov.

12.

Long-term disability progression in primary progressive multiple sclerosis: a 15-year study.

Rocca MA, Sormani MP, Rovaris M, Caputo D, Ghezzi A, Montanari E, Bertolotto A, Laroni A, Bergamaschi R, Martinelli V, Comi G, Filippi M.

Brain. 2017 Nov 1;140(11):2814-2819. doi: 10.1093/brain/awx250.

PMID:
29053836
13.

Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.

Sormani MP, Muraro PA, Schiavetti I, Signori A, Laroni A, Saccardi R, Mancardi GL.

Neurology. 2017 May 30;88(22):2115-2122. doi: 10.1212/WNL.0000000000003987. Epub 2017 Apr 28. Erratum in: Neurology. 2017 Jul 11;89(2):215.

PMID:
28455383
14.

Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS.

Bommarito G, Bellini A, Pardini M, Solaro C, Roccatagliata L, Laroni A, Capello E, Mancardi GL, Uccelli A, Inglese M.

Mult Scler. 2018 Apr;24(5):623-631. doi: 10.1177/1352458517704077. Epub 2017 Apr 10.

PMID:
28394195
15.

Approved drugs for multiple sclerosis: the challenge of choice.

Sormani MP, Laroni A.

Lancet Neurol. 2017 Apr;16(4):252-253. doi: 10.1016/S1474-4422(17)30021-2. Epub 2017 Feb 11. No abstract available.

PMID:
28209332
16.

Regulatory Functions of Natural Killer Cells in Multiple Sclerosis.

Gross CC, Schulte-Mecklenbeck A, Wiendl H, Marcenaro E, Kerlero de Rosbo N, Uccelli A, Laroni A.

Front Immunol. 2016 Dec 19;7:606. doi: 10.3389/fimmu.2016.00606. eCollection 2016. Review.

17.

In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma.

Gandoglia I, Ivaldi F, Carrega P, Armentani E, Ferlazzo G, Mancardi G, Kerlero de Rosbo N, Uccelli A, Laroni A.

Immunol Lett. 2017 Jan;181:109-115. doi: 10.1016/j.imlet.2016.11.015. Epub 2016 Dec 2.

PMID:
27919749
18.

Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.

Laroni A, Brogi D, Brescia Morra V, Guidi L, Pozzilli C, Comi G, Lugaresi A, Turrini R, Raimondi D, Uccelli A, Mancardi GL.

Neurol Sci. 2017 Jan;38(1):53-59. doi: 10.1007/s10072-016-2701-z. Epub 2016 Oct 18.

PMID:
27757552
19.

Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis.

Laroni A, Armentani E, Kerlero de Rosbo N, Ivaldi F, Marcenaro E, Sivori S, Gandhi R, Weiner HL, Moretta A, Mancardi GL, Uccelli A.

J Autoimmun. 2016 Aug;72:8-18. doi: 10.1016/j.jaut.2016.04.003. Epub 2016 May 4.

20.

Mesenchymal stem cells for the treatment of neurological diseases: Immunoregulation beyond neuroprotection.

Laroni A, de Rosbo NK, Uccelli A.

Immunol Lett. 2015 Dec;168(2):183-90. doi: 10.1016/j.imlet.2015.08.007. Epub 2015 Aug 18. Review.

PMID:
26296458
21.

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.

Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC, Marta M, Dalla Costa G, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño JC, Kleinová P, Horáková D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmestrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martínez AD, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr KM, Galimberti D, Rejdak K, Lycke J, Frederiksen JL, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg R, Yaldizli Ö, Vécsei L, Kieseier BC, Hartung HP, Villoslada P, Siva A, Saiz A, Tumani H, Havrdová E, Villar LM, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan SV, Giovannoni G.

Mult Scler. 2015 Jul;21(8):1013-24. doi: 10.1177/1352458514568827. Epub 2015 Feb 13.

PMID:
25680984
22.

Clinical baseline factors predict response to natalizumab: their usefulness in patient selection.

Laroni A, Gandoglia I, Solaro C, Ribizzi G, Tassinari T, Pizzorno M, Parodi S, Baldassarre G, Rilla MT, Venturi S, Capello E, Sormani MP, Uccelli A, Mancardi GL.

BMC Neurol. 2014 May 12;14:103. doi: 10.1186/1471-2377-14-103.

23.

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.

Laroni A, Brogi D, Morra VB, Guidi L, Pozzilli C, Comi G, Lugaresi A, Turrini R, Raimondi D, Uccelli A, Mancardi GL; EAP Investigators.

BMC Neurol. 2014 Apr 1;14:65. doi: 10.1186/1471-2377-14-65.

24.

Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system.

Laroni A, Novi G, Kerlero de Rosbo N, Uccelli A.

J Neuroimmune Pharmacol. 2013 Dec;8(5):1062-76. doi: 10.1007/s11481-013-9456-6. Epub 2013 Apr 12. Review.

PMID:
23579931
25.

Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption.

Laroni A, Brogi D, Milesi V, Abate L, Uccelli A, Mancardi G.

Mult Scler. 2013 Aug;19(9):1236-7. doi: 10.1177/1352458512468498. Epub 2012 Nov 26. No abstract available.

PMID:
23184503
26.

Mesenchymal stem cells as treatment for MS - progress to date.

Uccelli A, Laroni A, Freedman MS.

Mult Scler. 2013 Apr;19(5):515-9. doi: 10.1177/1352458512464686. Epub 2012 Nov 1. Review.

PMID:
23124791
27.

T-cell trafficking in the central nervous system.

Sallusto F, Impellizzieri D, Basso C, Laroni A, Uccelli A, Lanzavecchia A, Engelhardt B.

Immunol Rev. 2012 Jul;248(1):216-27. doi: 10.1111/j.1600-065X.2012.01140.x. Review.

PMID:
22725964
28.

Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification.

Laroni A, Giacomazzi CG, Grimaldi L, Gallo P, Sormani MP, Bertolotto A, McDermott JL, Gandoglia I, Martini I, Vitello G, Rinaldi F, Barzon L, Militello V, Pizzorno M, Bandini F, Capello E, Palù G, Uccelli A, Mancardi GL, Varnier OE.

J Neuroimmune Pharmacol. 2012 Sep;7(3):665-72. doi: 10.1007/s11481-012-9366-z. Epub 2012 May 16.

PMID:
22585413
29.

IL-27 imparts immunoregulatory function to human NK cell subsets.

Laroni A, Gandhi R, Beynon V, Weiner HL.

PLoS One. 2011;6(10):e26173. doi: 10.1371/journal.pone.0026173. Epub 2011 Oct 19.

30.

Can we kill an extra bird with the same stone?

Laroni A, Giacosa A, Uccelli A, Mancardi GL.

Inflamm Bowel Dis. 2011 Sep;17(9):E124-5. doi: 10.1002/ibd.21802. Epub 2011 Jun 24. No abstract available.

PMID:
21710537
31.

Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases.

Uccelli A, Laroni A, Freedman MS.

Lancet Neurol. 2011 Jul;10(7):649-56. doi: 10.1016/S1474-4422(11)70121-1. Review.

PMID:
21683930
32.

A case of thyroiditis during natalizumab therapy for multiple sclerosis.

Oddo S, Laroni A, Uccelli A, Giusti M.

J Endocrinol Invest. 2011 May;34(5):408-9. No abstract available.

PMID:
21677508
33.

Neuroprotective features of mesenchymal stem cells.

Uccelli A, Benvenuto F, Laroni A, Giunti D.

Best Pract Res Clin Haematol. 2011 Mar;24(1):59-64. doi: 10.1016/j.beha.2011.01.004. Epub 2011 Feb 25. Review.

PMID:
21396593
34.

Association of melanoma and natalizumab therapy in the Italian MS population: a second case report.

Laroni A, Bedognetti M, Uccelli A, Capello E, Mancardi GL.

Neurol Sci. 2011 Feb;32(1):181-2. doi: 10.1007/s10072-010-0427-x. Epub 2010 Nov 5.

PMID:
21052756
35.

Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells.

Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, Laroni A, Kozoriz D, Weiner HL, Quintana FJ.

Nat Immunol. 2010 Sep;11(9):846-53. doi: 10.1038/ni.1915. Epub 2010 Aug 1.

36.

Three years of experience: the Italian registry and safety data update.

Mancardi GL, Tedeschi G, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, Rossi P, Savettieri G, Tola MR, Comi G, Pozzilli C, Bertolotto A, Marrosu MG, Grimaldi LM, Laroni A, Vanacore N, Covezzoli A, De Rosa M, Piccinni C, Montanaro N, Periotto L, Iommelli R, Tomino C, Provinciali L.

Neurol Sci. 2011 Jan;31 Suppl 3:295-7. doi: 10.1007/s10072-010-0356-8.

PMID:
20644975
37.

Role of the innate immune system in the pathogenesis of multiple sclerosis.

Gandhi R, Laroni A, Weiner HL.

J Neuroimmunol. 2010 Apr 15;221(1-2):7-14. doi: 10.1016/j.jneuroim.2009.10.015. Review.

38.

Wernicke's syndrome during parenteral feeding: not an unusual complication.

Francini-Pesenti F, Brocadello F, Manara R, Santelli L, Laroni A, Caregaro L.

Nutrition. 2009 Feb;25(2):142-6. doi: 10.1016/j.nut.2008.08.003. Epub 2008 Oct 16.

PMID:
18929463
39.

Multiple sclerosis and autoimmune diseases: epidemiology and HLA-DR association in North-east Italy.

Laroni A, Calabrese M, Perini P, Albergoni MP, Ranzato F, Tiberio M, Battistin L, Gallo P.

J Neurol. 2006 May;253(5):636-9. Epub 2006 Mar 6.

PMID:
16502215

Supplemental Content

Loading ...
Support Center